what happens after stopping glp 1 When Patients Stop Taking GLP-1 Medications? New analysis of GLP-1 drugs

Interestingly, based on the current studies, the liver-cell axis may be extremely sensitive to minor alterations in hepatic fat content, to other components in the NAS, and to fibrosis (62)

10.1210/en.2013-1142 84

Beyond the indirect benefits of weight loss on inflammation, research is also examining whether GLP-1 medications directly affect other inflammatory processes

Speak to your doctor for advice

We provide comprehensive care, including in-depth medical evaluations, personalized treatment plans, ongoing progress monitoring, and lifestyle guidance to support safe, effective, and sustainable results

Estimates from a meta-analysis suggest that the global prevalence of nonalcoholic fatty liver disease (NAFLD) is 30.1%, with a significant increase from 25.3% (19902006) to 38.2% (20162019) over the last three decades